Clinical Trials Logo

Clinical Trial Summary

1. Clinical Objective : To improve the growth of these children

2. Genetic objective : A study of the genetics of the syndrome


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00452725
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 3
Start date October 1997
Completion date July 2010

See also
  Status Clinical Trial Phase
Completed NCT01529944 - Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 Phase 3
Recruiting NCT05761314 - Solid Tumors in RASopathies N/A
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Recruiting NCT06267807 - Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders N/A
Enrolling by invitation NCT05308927 - French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
Recruiting NCT04395495 - RASopathy Biorepository
Completed NCT01529840 - Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome Phase 3
Recruiting NCT06355622 - Prevalence and Characterization of Pain in RASopathies N/A
Recruiting NCT05202210 - Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome
Completed NCT02713945 - Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome Phase 3
Recruiting NCT05361811 - Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial N/A
Completed NCT03435627 - Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
Recruiting NCT05723835 - A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Phase 3
Completed NCT02486731 - Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes
Completed NCT01927861 - Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome Phase 3
Recruiting NCT04888936 - Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
Recruiting NCT06331117 - Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies N/A
Completed NCT00960128 - Observational Prospective Study on Patients Treated With Norditropin® N/A
Terminated NCT00351221 - Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome Phase 2